Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A, Fragakis N, Rizzo M. Karakasis P, et al. Among authors: patoulias d. Metabolism. 2023 Dec;149:155710. doi: 10.1016/j.metabol.2023.155710. Epub 2023 Oct 16. Metabolism. 2023. PMID: 37852529
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D, Stavropoulos K, Imprialos K, Katsimardou A, Kalogirou MS, Koutsampasopoulos K, Zografou I, Papadopoulos C, Karagiannis A, Doumas M. Patoulias D, et al. Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13. Diabetes Res Clin Pract. 2019. PMID: 31733280
Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D, Katsimardou A, Kalogirou MS, Zografou I, Toumpourleka M, Imprialos K, Stavropoulos K, Stergiou I, Papadopoulos C, Doumas M. Patoulias D, et al. Diabetes Metab. 2020 Sep;46(4):272-279. doi: 10.1016/j.diabet.2020.04.001. Epub 2020 May 8. Diabetes Metab. 2020. PMID: 32437914
248 results